These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 18698545

  • 1. The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value.
    Lewandowski M, Kornacewicz-Jach Z, Millo B, Zielonka J, Czechowska M, Kaliszczak R, Płońska E, Goracy J, Kaźmierczak J, Naruszewicz M.
    Cardiol J; 2008; 15(4):357-64. PubMed ID: 18698545
    [Abstract] [Full Text] [Related]

  • 2. The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.
    Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Kotsopoulou M, Tsioufis C, Stefanadis C.
    Int J Cardiol; 2006 Apr 28; 109(1):48-52. PubMed ID: 16002160
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R.
    Am Heart J; 2005 Mar 28; 149(3):451-7. PubMed ID: 15864233
    [Abstract] [Full Text] [Related]

  • 4. Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
    Miedema MD, Conover CA, MacDonald H, Harrington SC, Oberg D, Wilson D, Henry TD, Schwartz RS.
    Am J Cardiol; 2008 Jan 01; 101(1):35-9. PubMed ID: 18157962
    [Abstract] [Full Text] [Related]

  • 5. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.
    Circulation; 2003 Sep 30; 108(13):1560-6. PubMed ID: 12975259
    [Abstract] [Full Text] [Related]

  • 6. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
    Chyrchel M, Rakowski T, Rzeszutko L, Legutko J, Dziewierz A, Dubiel JS, Dudek D.
    Kardiol Pol; 2006 Dec 30; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
    [Abstract] [Full Text] [Related]

  • 7. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
    van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R.
    J Nephrol; 2003 Dec 30; 16(2):238-44. PubMed ID: 12768071
    [Abstract] [Full Text] [Related]

  • 8. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S, MIRACL Study Investigators.
    J Am Coll Cardiol; 2009 Jun 09; 53(23):2186-96. PubMed ID: 19497447
    [Abstract] [Full Text] [Related]

  • 9. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J, ACTFAST investigators.
    Am Heart J; 2007 May 09; 153(5):881-8. PubMed ID: 17452168
    [Abstract] [Full Text] [Related]

  • 10. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T, Akar Bayram N, Kayhan T, Canbay A, Sahin D, Durmaz T, Ozdemir O, Aydoğdu S, Diker E.
    Anadolu Kardiyol Derg; 2008 Dec 09; 8(6):407-12. PubMed ID: 19103535
    [Abstract] [Full Text] [Related]

  • 11. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
    Yang J, Li XP, Zhao SP, Li J, Li JD, Xie XM.
    Clin Chim Acta; 2006 Jun 09; 368(1-2):183-7. PubMed ID: 16472797
    [Abstract] [Full Text] [Related]

  • 12. Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.
    Kuklińska AM, Musiał WJ, Kamiński KA, Kralisz P, Modrzejewski W, Sobkowicz B, Dobrzycki S, Stec S, Wojtkowska I.
    Rocz Akad Med Bialymst; 2005 Jun 09; 50():339-42. PubMed ID: 16358997
    [Abstract] [Full Text] [Related]

  • 13. The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
    Bolewski A, Lipiecki J, Plewa R, Burchardt P, Siminiak T.
    Cardiology; 2008 Jun 09; 111(2):140-6. PubMed ID: 18376126
    [Abstract] [Full Text] [Related]

  • 14. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome.
    Zhou T, Zhou SH, Qi SS, Shen XQ, Zeng GF, Zhou HN.
    Clin Chim Acta; 2006 Jun 09; 368(1-2):168-72. PubMed ID: 16480969
    [Abstract] [Full Text] [Related]

  • 15. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP, Peng DQ, Yu BL, Huo Y, CHILLAS investigators.
    Am Heart J; 2009 Oct 09; 158(4):509-512.e1. PubMed ID: 19781407
    [Abstract] [Full Text] [Related]

  • 16. Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
    Nawawi H, Osman NS, Yusoff K, Khalid BA.
    Horm Metab Res; 2003 Aug 09; 35(8):479-85. PubMed ID: 12953165
    [Abstract] [Full Text] [Related]

  • 17. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
    Chyrchel M, Dudek D, Bartuś S, Legutko J, Heba G, Dubiel JS.
    Kardiol Pol; 2004 Sep 09; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
    [Abstract] [Full Text] [Related]

  • 18. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
    Takebayashi K, Matsumoto S, Wakabayashi S, Inukai Y, Matsutomo R, Aso Y, Inukai T.
    Metabolism; 2005 Sep 09; 54(9):1225-9. PubMed ID: 16125534
    [Abstract] [Full Text] [Related]

  • 19. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.
    de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E.
    J Am Coll Cardiol; 2007 Nov 27; 50(22):2117-24. PubMed ID: 18036447
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina.
    Zhao Z, Geng J, Ge ZM, Wang W, Zhang Y, Kang WQ.
    Clin Exp Pharmacol Physiol; 2009 May 27; 36(5-6):554-8. PubMed ID: 19673939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.